ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer

BACKGROUND: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%. MATERIALS AND METHODS: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1...

Descripción completa

Detalles Bibliográficos
Autores principales: Suryavanshi, Moushumi, Panigrahi, Manoj Kumar, Kumar, Dushyant, Verma, Haristuti, Saifi, Mumtaz, Dabas, Bharti, Batra, Ullas, Doval, Dinesh, Mehta, Anurag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592750/
https://www.ncbi.nlm.nih.gov/pubmed/28869223
http://dx.doi.org/10.4103/lungindia.lungindia_116_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592750/
https://www.ncbi.nlm.nih.gov/pubmed/28869223
http://dx.doi.org/10.4103/lungindia.lungindia_116_17

Ejemplares similares